CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

https://doi.org/10.5281/zenodo.18029894

Available online at: http://www.iajps.com *Review Article*

SPHERICAL AGGLOMERATION TECHNIQUES IN PHARMACEUTICAL PARTICLE ENGINEERING A COMPREHENSIVE DEEP-DIVE REVIEW FOR MODERN SOLID DOSAGE FORM DEVELOPMENT

P.Saranya*, CH.Bhargavi, G.Chandhini, M.RamiReddy, V. Nithin Reddy and V.Saikishore
Bapatla College of Pharmacy , Bapatla-522101

Abstract:
The pharmaceutical industry is currently facing significant challenges in the development of solid dosage forms due to the increasing prevalence of poorly soluble, highly potent drug molecules. A substantial proportion of newly developed active pharmaceutical ingredients (APIs) fall under Biopharmaceutics Classification System (BCS) Class II, characterized by low aqueous solubility and high permeability. Conventional manufacturing techniques such as wet and dry granulation often fail to deliver the desired flowability, compressibility, and dissolution performance required for efficient tablet production and optimal bioavailability. ***Spherical agglomeration*** *has emerged as a novel and efficient particle engineering technique that integrates crystallization, agglomeration, and granulation into a single step. By employing a carefully selected ternary solvent system consisting of a good solvent, poor solvent, and bridging liquid, this technique enables the formation of dense, spherical agglomerates with superior micromeritic properties. Advanced spherical agglomeration methods such as Quasi-Emulsion Solvent Diffusion (QESD), Ammonia Diffusion Method (ADM), and Neutralization techniques allow precise control over particle size, morphology, and mechanical strength.This article provides a comprehensive and technically detailed review of spherical agglomeration techniques, focusing on fundamental mechanisms, physicochemical principles, process methodologies, pharmaceutical applications, and industrial challenges. Special emphasis is placed on* ***direct compression applications***, ***bioavailability enhancement of hydrophobic drugs***, *and the integration of Quality by Design (QbD) concepts for industrial scalability. The review highlights spherical agglomeration as a paradigm-shifting approach in pharmaceutical particle engineering.*

Keywords: *Spherical Agglomeration, Particle Engineering, Quality by Design*

Corresponding author:
P.Saranya,
Department of Pharmaceutics,
Bapatla College of Pharmacy,
Bapatla-522101.A.P

QR CODE

Please cite this article in press P.Saranya ***et al., Spherical agglomeration techniques in pharmaceutical particle engineering A comprehensive deep-dive review for modern solid dosage form development*** *, Indo Am. J. P. Sci, 2025; 12(12).*

1. INTRODUCTION:

Evolution of Particle Engineering in Pharmaceutics

Particle engineering plays a pivotal role in pharmaceutical technology by modifying the physical and mechanical properties of drug particles to enhance manufacturability and therapeutic efficacy. Traditionally, particle size reduction, granulation, and coating have been employed to improve flowability, compressibility, and dissolution behavior. However, with the evolution of drug discovery, modern APIs are increasingly complex, lipophilic, and poorly water soluble, rendering conventional approaches insufficient [1].

Failure of Traditional Granulation for Modern Potent Drugs

Conventional granulation techniques were developed primarily for crystalline drugs with acceptable physicochemical properties. In contrast, modern potent drugs often exhibit:

- Poor flowability due to irregular particle shape
- High cohesiveness and electrostatic charging
- Low compressibility
- Poor aqueous solubility

Wet granulation, although effective in improving flow, involves multiple processing steps, exposure to moisture, and thermal stress during drying. These conditions can lead to degradation of moisture-sensitive and thermolabile drugs. Dry granulation, while avoiding moisture, produces granules with poor mechanical strength and non-uniform size distribution, especially problematic for low-dose potent drugs.

As a result, traditional granulation often fails to meet the requirements of **direct compression**, which is increasingly preferred due to its simplicity, cost-effectiveness, and reduced processing time[2].

Emergence of Spherical Agglomeration

Spherical agglomeration was introduced as an advanced particle engineering technique capable of overcoming the limitations of conventional granulation. Unlike traditional methods, spherical agglomeration modifies particle characteristics during crystallization itself, producing spherical agglomerates with enhanced flow, compressibility, and dissolution properties.

This technique has gained significant attention due to its ability to:

- Combine crystallization and granulation into a single step
- Produce directly compressible particles
- Enhance dissolution and bioavailability of poorly soluble drugs

2. Fundamental Mechanism of Spherical Agglomeration

The Three-Phase System: Spherical agglomeration is based on a **three-phase solvent system**:

1. **Good Solvent (Internal Phase):** Completely dissolves the drug to form a saturated solution.
2. **Poor Solvent (External Phase):** Miscible with the good solvent but has low drug solubility, causing precipitation.
3. **Bridging Liquid:** Immiscible with the poor solvent but has affinity for the drug, enabling particle binding.

Stages of Agglomerate Formation

Nucleation: Supersaturation leads to formation of fine drug crystals when the good solvent diffuses into the poor solvent.

Transition Phase: Crystals collide and adhere through liquid bridges formed by the bridging liquid.

Ball Growth Phase: Agglomerates grow into spherical structures through layering and coalescence.

Capillary and Funicular States in Particle Bonding

- **Pendular State:** Initial liquid bridges at contact points.
- **Funicular State:** Partial filling of voids with liquid, increased bonding.
- **Capillary State:** Complete saturation, strongest inter-particle cohesion.

Capillary forces generated during these states determine agglomerate strength and stability.

3. Spherical Agglomeration Techniques (In-Depth Explanation): Spherical agglomeration is not a single fixed method but a **group of solvent-mediated particle engineering techniques**. Each technique is designed to handle drugs with different **solubility behavior, pH sensitivity, and crystallization characteristics**. The fundamental objective across all techniques remains the same to convert fine, irregular drug crystals into dense, spherical, free-flowing agglomerates [3].

3.1 Quasi-Emulsion Solvent Diffusion (QESD)

Quasi-Emulsion Solvent Diffusion is the **most widely studied and industrially relevant spherical agglomeration technique**, especially for poorly soluble drugs.

Principle: QESD is based on the formation of **quasi-emulsion droplets** when a drug solution (good solvent) is introduced into a poor solvent under controlled agitation. These droplets behave like temporary micro-reactors where crystallization and agglomeration occur simultaneously [4].

Step-by-Step Mechanism

1. **Drug Dissolution:** The drug is completely dissolved in a good solvent (e.g., acetone, ethanol).
2. **Dispersion into Poor Solvent:** This solution is poured into a poor solvent (e.g., water) under stirring, leading to formation of fine droplets.
3. **Solvent Diffusion:** The good solvent diffuses out into the poor solvent, reducing drug solubility inside droplets.

4. **Crystallization Inside Droplets:** Supersaturation occurs, leading to nucleation and crystal growth.
5. **Agglomeration by Bridging Liquid:** A bridging liquid (partially miscible with good solvent) creates liquid bridges between crystals, forming spherical agglomerates.

Why QESD Is Important [5]

- Produces **uniform, spherical particles**
- Excellent control over particle size
- Enhances **flow, compressibility, and dissolution**
- Ideal for **BCS Class II drugs**

3.2 Ammonia Diffusion Method (ADM)

The Ammonia Diffusion Method is specifically designed for **acidic drugs** whose solubility is influenced by pH.

Principle: This method utilizes **controlled diffusion of ammonia gas or ammonia solution** to change the pH of the system gradually, triggering crystallization and agglomeration [6].

Mechanism

- Acidic drug is dissolved in a suitable solvent system.
- Ammonia diffuses slowly into the medium.
- Increase in pH reduces drug solubility.
- Controlled precipitation occurs.
- Bridging liquid binds crystals into spherical agglomerates.

Advantages

- Avoids sudden precipitation
- Produces strong agglomerates
- Suitable for NSAIDs and weak acids

Limitations

- Requires precise pH control
- Scale-up is complex

3.3 Neutralization Technique

This technique is used when the drug shows **pH-dependent solubility**.

Principle: Agglomeration is induced by **neutralizing a drug solution**, causing gradual precipitation and agglomerate formation [7].

Key Features

- Acidic drug + alkaline solution (or vice versa)
- Neutralization lowers solubility
- Controlled crystal formation
- Bridging liquid induces spherical growth

Significance

- Suitable for **ionizable drugs**
- Better control compared to rapid precipitation methods

4. Mathematical and Physical Aspects of Spherical Agglomeration

Spherical agglomeration is strongly governed by **interfacial science and particle physics**, not just chemistry [8].

4.1 Droplet Formation and Interfacial Tension

When a drug solution is dispersed in a poor solvent, droplet formation depends on:

- **Interfacial tension (γ)**
- **Agitation speed**
- **Viscosity of phases**

Lower interfacial tension results in **smaller, stable droplets**, which leads to **uniform agglomerates**.

Conceptual explanation:

Interfacial tension resists droplet breakup, while mechanical stirring promotes droplet division. A balance between these forces defines droplet size.

4.2 Capillary Forces and Particle Bonding

Capillary State

- Voids between particles are fully filled with liquid
- Strongest cohesive force
- Leads to dense, mechanically strong agglomerates

Funicular State

- Liquid partially fills voids
- Moderate bonding
- Important for controlled growth

Capillary pressure pulls particles together, stabilizing spherical structure.

4.3 Growth Kinetics of Agglomerates

Agglomerate growth follows:

- Nucleation rate
- Collision frequency
- Liquid bridge stability

Excessive agitation may cause **breakage**, while low agitation results in **irregular shapes**.

5. Pharmaceutical Applications

5.1 Direct Compression – Industrial Relevance

Spherical agglomerates possess:

- Low angle of repose
- High bulk density
- Uniform particle size

This allows **direct compression without granulation**, reducing:

- Processing time
- Equipment cost
- Batch variability

This is extremely valuable for **high-potency drugs** [9].

5.2 Bioavailability Enhancement of BCS Class II Drugs

BCS Class II drugs suffer from dissolution-limited absorption[10].

Spherical agglomeration improves bioavailability by:

- Increasing wettability
- Creating porous internal structure
- Reducing crystallinity
- Enhancing surface area

6. Case Studies

6.1 Celecoxib (BCS Class II Drug)

Celecoxib has:

- Poor aqueous solubility
- Poor compressibility

After spherical agglomeration:

- Flow properties improved
- Tablets prepared by direct compression
- Faster dissolution observed due to improved wettability

6.2 Ketoprofen (NSAID)

Ketoprofen exhibits:

- Irregular crystal shape
- Poor flow

Agglomerated ketoprofen showed:

- Spherical morphology
- Enhanced dissolution rate
- Improved tablet hardness at lower compression force

7. Challenges and Future Trends

7.1 Industrial Scale-Up Challenges

- Solvent recovery and toxicity
- Reproducibility of particle size
- Equipment limitations
- Environmental concerns

7.2 Quality by Design (QbD) Approach

QbD helps identify:

- **Critical Material Attributes (CMAs)**
- **Critical Process Parameters (CPPs)**

This ensures:

- Consistent product quality
- Regulatory compliance
- Robust large-scale manufacturing

7.3 Future Trends [11-12]

- Continuous spherical agglomeration
- Green solvents
- Process automation
- AI-based particle control

8. CONCLUSION:

Spherical agglomeration is a scientifically advanced and industrially promising particle engineering technique that directly addresses the limitations of conventional granulation methods. By integrating crystallization and agglomeration into a single step, it enhances flowability, compressibility, and dissolution behavior of poorly soluble drugs. Advanced techniques such as QESD, ADM, and neutralization provide flexibility in handling complex APIs. With the integration of Quality by Design principles and modern automation, spherical agglomeration has the potential to become a standard manufacturing approach for next-generation solid dosage forms.

REFERENCES:

1. Kawashima, Y. Spherical crystallization as a particle design technique for pharmaceutical solids. Powder Technology2017;, 30: 1–10.
2. Nokhodchi, A., Maghsoodi, M., & Hassan-Zadeh, D. Spherical crystallization: Recent advances and pharmaceutical applications. International Journal of Pharmaceutics, 2018;545(1–2): 38–49.
3. Chow, A. H. L., Tong, H. H. Y., Chattopadhyay, P., & Shekunov, B. Y. (2019). Particle engineering for pharmaceutical applications. *Advanced Drug Delivery Reviews.2019; 131*:99–113.
4. Rasenack, N., & Müller, B. W. Crystal habit and tableting behavior. *European Journal of Pharmaceutics and Biopharmaceutics2016; 101*:1–12.
5. Patel, M. A., AbouGhaly, M. H., Schryer-Praga, J. V., & Chadwick, K. (2020). Applications of spherical agglomeration in direct compression. *AAPS PharmSciTech, 2020;21*(4):1–12.
6. Maghsoodi, M. Spherical agglomeration of celecoxib for improving flowability and dissolution. *Drug Development and Industrial Pharmacy, 2017;43*(2), 238–247.
7. York, P. Strategies for particle design using crystallization and agglomeration. *Drug Development and Industrial Pharmacy,2016; 42*(6): 847–856.
8. Bhardwaj, V., & Bansal, A. K. Improving solubility and dissolution of BCS class II drugs. *International Journal of Pharmaceutics2019;, 557*:1–14.
9. Li, M., Yaragudi, N., & Wu, C. Y. Scale-up challenges in pharmaceutical agglomeration processes. *Powder Technology,2020; 36:* 37–48.
10. Zhai, X., Feng, Y., & Wang, J. (2021). Application of Quality by Design in particle engineering. *Journal of Pharmaceutical Sciences, 2021;110*(9): 3080–3092.
11. Thati J, Chinta S. A Review on Spherical Crystallization Mechanisms and Characterization. Research Journal of Pharmacy and Technology. 2018; 11(1):412-7.
12. Shivakumar HN, Somasekhar V, Roy A. Preparation and Characterization of Directly Compressible Spherical Agglomerates of Etoricoxib. Indian J of Pharmaceutical Education and Research. 2020;54(4):983-90.